Navigation

    Forum

    • Register
    • Login
    • Search
    • Categories
    • Recent
    • Popular
    • Users
    • Groups

    Branded and Unbranded APS in Conference Setting

    Non-product branded APS, pre-NOC teasers
    2
    4
    172
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • G
      georgian21 last edited by

      In a conference setting, is it possible to display unbranded Disease State advertising (helping educate about the disease prior to the launch of Drug A) along with branded content for Drugs B and C (which are already in the market)?

      Jennifer Carroll 1 Reply Last reply Reply Quote 0
      • Jennifer Carroll
        Jennifer Carroll @georgian21 last edited by

        Hey @georgian21

        As a general rule of thumb, branded and unbranded should be separate and distinct. The difficulty in having unbranded content presented in the same booth as branded content is that it has the potential to create an association between the two (i.e. it brands the unbranded pieces) which is not generally permitted due to the potential for off-label implications.

        G 1 Reply Last reply Reply Quote 0
        • G
          georgian21 @Jennifer Carroll last edited by

          @jennifer-carroll Thank you.

          Just to clarify, Drug A (unbranded) and Drugs B/C (branded) would belong to different disease areas.

          Would that change the PAAB ruling?

          Jennifer Carroll 1 Reply Last reply Reply Quote 0
          • Jennifer Carroll
            Jennifer Carroll @georgian21 last edited by

            Hey @georgian21

            This does give us pause to consider the nuance of the scenario. The main concern is separation. When we put unbranded content with branded, it creates an association that brands everything. Even if it is a separate therapeutic area, the question is, can we ensure that there is no suggestion that the product has implications (e.g. safety/efficacy) in that therapeutic area? We’d also have to consider the therapeutic areas as some are more closely related than others.

            Example:
            - Drug A (renal or CV drug); Drug B/C (diabetes)
            - Drug A (lipid drug); Drug B/C (HIV)

            This type of question might be more suited for an opinion so that we may assess the intricacies.

            1 Reply Last reply Reply Quote 0
            • First post
              Last post